AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38877571
Drug: Anaemia (Hb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaemia (Hb < 9.5 g/dL)
Trial: 38877608
Drug: Adapted Test-and-Exercise
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Test-and-Exercise home-based exercise program (8 weeks, once per week with a physiotherapist, twice per week with caregiver or independently)
Trial: 38878209
Drug: Modafinil 400
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 400 mg QD from Day 15 to Day 21
Trial: 38878209
Drug: Encorafenib 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib 450 mg QD from Day 1
Trial: 38878209
Drug: Binimetinib 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib 45 mg BID from Day 1
Trial: 38878337
Drug: Internet-based ACT
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based ACT combined with Treatment as Usual (iACT + TAU)
Trial: 38879045
Drug: Through-the-needle injection-capable
RxNorm normalized name: BRIEF,TRANQUILITY ALL THROUGH THE NIGHT BRIEF MEDIUM #2185
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Through-the-needle injection-capable electrosurgical knife
Trial: 38879393
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (cohort 1)
Trial: 38879393
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (cohort 2)
Trial: 38879455
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) pulse oximetry combining oxygenation, perfusion data, and pulse delay at 2 time points
Trial: 38879455
Drug: ML algorithms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML algorithms at 1 versus 2 time points with/without pulse delay
Trial: 38879518
Drug: Delayed Cold-Stored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Cold-Stored Platelets (DCSP) - ABO-identical, buffy-coat, pathogen-reduced platelets in platelet additive solution maintained at 22 °C for up to 4 days then placed at 4 °C for a minimum of 24 h, with expiration at 14 days after collection. Duration: from termination of cardiopulmonary bypass to 24 h after, with a maximum of two doses.
Trial: 38879571
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Pycnogenol® daily for 12 weeks
Trial: 38879802
Drug: Linvoseltamab 200
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linvoseltamab 200 mg
Trial: 38879802
Drug: Linvoseltamab 50
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linvoseltamab 50 mg
Trial: 38879879
Drug: SPS tablets
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPS tablets (n = 60; three tablets per dose, twice daily) for 24 weeks
Trial: 38880111
Drug: RH5.1/Matrix-M vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RH5.1/Matrix-M vaccine candidate (10 μg RH5.1 at 0, 1, and 2 months for Adults 10M; 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months for Adults DFx; 10 μg RH5.1 at 0, 1, and 2 months for Children 10M; 10 μg RH5.1 at 0, 1, and 6 months for Children 10D; Children DFx and High Children DFx with dose-escalation regimen)
Trial: 38880111
Drug: Delayed third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed third dose regimen (Children 10D)
Trial: 38880111
Drug: RH5.1/Matrix-M vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RH5.1/Matrix-M vaccine candidate
Trial: 38880198
Drug: High-dose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (200 ppm for 30 min) + continuous low-dose (20 ppm) iNO
Trial: 38880198
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose iNO
Trial: 38880251
Drug: dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dupilumab 300 mg every 2 weeks
Trial: 38880785
Drug: Ad26.RSV.preF/RSV preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF/RSV preF protein vaccine (1 × 10 dose)
Trial: 38880785
Drug: Ad26.RSV.preF/RSV preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF/RSV preF protein vaccine
Trial: 38880932
Drug: BI 474121
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 474121 (3.0 mg/kg)
Trial: 38880956
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 or 10 mg twice daily)
Trial: 38881506
Drug: Heplisav-B (HepB-CpG)
RxNorm normalized name: HepB-CpG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heplisav-B (HepB-CpG) 2-dose series
Trial: 38881506
Drug: Heplisav-B (HepB-CpG)
RxNorm normalized name: HepB-CpG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heplisav-B (HepB-CpG) 1-dose
Trial: 38881599
Drug: EYP-1901 (440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYP-1901 (440 μg, 1030 μg, 2060 μg, 3090 μg)
Trial: 38881900
Drug: Monoclonal anti-idiotypic
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal anti-idiotypic (anti-ID) antibody positive controls
Trial: 38883740
Drug: Ribociclib (CDK4/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor)
Trial: 38883743
Drug: Self-administered intravaginal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2g every other week for eight applications.
Trial: 38883743
Drug: Self-administered intravaginal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream
Trial: 38883779
Drug: Intratumoral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratumoral administration of anti-CD40 agonistic antibody (2141-V11)
Trial: 38884332
Drug: Reteplase (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reteplase (18 mg bolus followed by another 18 mg bolus 30 minutes later)
Trial: 38884987
Drug: Nicotine-containing electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-containing electronic cigarettes (ECs) 18 mg/mL with placebo tablets
Trial: 38884987
Drug: Varenicline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline with standard dosing and nicotine-free ECs
Trial: 38884987
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets with nicotine-free ECs
Trial: 38885234
Drug: Glenzocimab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenzocimab (1000 mg/day for 3 days)
Trial: 38885246
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg by mouth twice daily
Trial: 38885481
Drug: BAFF-R CAR
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAFF-R CAR T-cell therapy
Trial: 38885482
Drug: SARS-CoV-2-specific CTLs
RxNorm normalized name: SARS-COV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2-specific CTLs (1 of 4 escalating doses, containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells)
Trial: 38885672
Drug: Sovleplenib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib (300 mg once daily for 24 weeks)
Trial: 38885985
Drug: Concurrent Substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Substance Use and Hazardous Drinking (SU and HD)
Trial: 38885990
Drug: qER solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qER solution with prioritised flag in the radiology information system (post-implementation phase)
Trial: 38886159
Drug: Entinostat 5
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat 5 mg weekly
Trial: 38886347
Drug: FS-1502 (anti-HER2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS-1502 (anti-HER2 ADC) at recommended phase 2 dose (RP2D) of 2.3 mg/kg once every 3 weeks.
Trial: 38886347
Drug: FS-1502 (anti-HER2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS-1502 (anti-HER2 ADC) at doses of 3.0 and 3.5 mg/kg.
Trial: 38886347
Drug: FS-1502 (anti-HER2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS-1502 (anti-HER2 ADC) at RP2D of 2.3 mg/kg.
Trial: 38888616
Drug: zanubrutinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zanubrutinib (160 mg twice-daily)
Trial: 38888616
Drug: ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib (420 mg once-daily)
Trial: 38888958
Drug: 8-week MBCT
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week MBCT intervention plus treatment as usual (MBCT + TAU)
Trial: 38889160
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment for psychotic disorders
Trial: 38889247
Drug: mRNA-1345 50-µg
RxNorm normalized name: mRNA-1345
DrugBank: mRNA-1345 (DB18739)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1345 50-µg vaccine
Trial: 38889372
Drug: European Organisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European Organisation for Research and Treatment of Cancer QoL Core 30 questionnaire (QLQ-C30) summary score at diagnosis and 1 and 2 years postdiagnosis.
Trial: 38889373
Drug: Amcenestrant 200
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant 200 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Trial: 38889373
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Trial: 38889431
Drug: Topical sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sildenafil cream (3.6%)
Trial: 38889737
Drug: Epcoritamab monotherapy
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epcoritamab monotherapy
Trial: 38890186
Drug: Low-level light/laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light/laser therapy (LLLT)
Trial: 38890563
Drug: MaxiPost (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MaxiPost (0.05 mg/min)
Trial: 38890641
Drug: eliapixant 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eliapixant 25 mg BID
Trial: 38890641
Drug: eliapixant 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eliapixant 75 mg BID
Trial: 38890641
Drug: eliapixant 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eliapixant 150 mg BID
Trial: 38890641
Drug: elagolix 150
RxNorm normalized name: elagolix 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elagolix 150 mg once daily
Trial: 38890655
Drug: IV-DXN (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-DXN (4 mg/ml DXN)
Trial: 38890655
Drug: PN-DXN (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-DXN (1 ml of 4 mg/ml DXN)
Trial: 38890709
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help 14-day Acceptance and Commitment Therapy (ACT) training
Trial: 38891799
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy for 12 weeks
Trial: 38893184
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) boost, single dose of 20 Gy, administered immediately after tumor resection.
Trial: 38895199
Drug: Oral fluoropyrimidine
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluoropyrimidine treatment
Trial: 38896141
Drug: fSCIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fSCIG 10% with conventional ramp-up at 1.0 g/kg/infusion
Trial: 38896141
Drug: fSCIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fSCIG 10% with no ramp-up at 1.0 g/kg/infusion
Trial: 38896141
Drug: fSCIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fSCIG 10% with accelerated ramp-up at 1.0 g/kg/infusion
Trial: 38896141
Drug: fSCIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fSCIG 10% with conventional ramp-up at 0.4 g/kg/infusion
Trial: 38896199
Drug: Mirogabalin 15
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 15 mg twice daily (after uptitration from 5 mg twice daily for the first week)
Trial: 38896264
Drug: Alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alglucosidase alfa treatment for ≤13 years
Trial: 38896602
Drug: Delgocitinib ointment
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Delgocitinib ointment
Trial: 38896602
Drug: Topical JAK
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical JAK inhibition
Trial: 38896602
Drug: Afatinib (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (EGFR inhibitor)
Trial: 38897097
Drug: Oral nomegestrol
RxNorm normalized name: nomegestrol
DrugBank: Nomegestrol acetate (DB13981)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral nomegestrol acetate/estradiol 1.5 mg/2.5 mg/day for 14 days (random start)
Trial: 38897097
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pharmaceutical treatment)
Trial: 38897103
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment and care)
Trial: 38897155
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments (248 treatments administered)
Trial: 38897155
Drug: Short delay
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short delay from onset of relapse to treatment initiation
Trial: 38897584
Drug: Mild hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hyperthermia with MR-guided high intensity focused ultrasound (MR-HIFU) combined with concurrent chemoradiation (30.6 Gy in 1.8 Gy fractions with capecitabine)
Trial: 38898018
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg on day 1 plus modified TPF (docetaxel 75 mg/m2) for three cycles
Trial: 38898120
Drug: Entrectinib 600
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Entrectinib 600 mg daily
Trial: 38898537
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual condition (TAU +)
Trial: 38898573
Drug: Cardiac shockwave
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shockwave therapy (SWT)
Trial: 38899599
Drug: Steps 1-2
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steps 1-2 (non-surgical) of periodontal therapy (test group; n=37)
Trial: 38899599
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group; n=37)
Trial: 38899693
Drug: ViPOR (venetoclax,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) administered every 21 days for six cycles
Trial: 38899695
Drug: CM313 (anti-CD38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM313 (anti-CD38 monoclonal antibody) administered intravenously at a dose of 16 mg/kg every week for 8 weeks
Trial: 38899695
Drug: CM313 (anti-CD38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM313 (anti-CD38 monoclonal antibody)
Trial: 38899776
Drug: Gamified delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamified delivery group (on-demand exercise videos and weekly exercise duration leaderboards)
Trial: 38900037
Drug: Ibrutinib in
RxNorm normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib in combination with R-GemOx (rituximab, gemcitabine, and oxaliplatin)
Trial: 38900037
Drug: Ibrutinib in
RxNorm normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib in combination with R-GemOx
Trial: 38900435
Drug: SOR-TACE (sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOR-TACE (sorafenib 400 mg twice daily plus on-demand TACE)
Trial: 38900984
Drug: SHR-A1811 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 (1.0 to 8.0 mg/kg, IV, once every 3 weeks)
Trial: 38900987
Drug: Fianlimab 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab 1,600 mg and cemiplimab 350 mg intravenously once every 3 weeks for up to 51 weeks (with optional additional 51 weeks if clinically indicated)
Trial: 38901008
Drug: Deutetrabenazine, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine, mean dose at week 145: 40.4 mg/d for psychotic disorders, 38.5 mg/d for mood and other disorders, 39.9 mg/d for those receiving DRAs, 38.5 mg/d for those not receiving DRAs.
Trial: 38901293
Drug: Subcutaneous drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drain insertion
Trial: 38901293
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no subcutaneous drain)
Trial: 38901559
Drug: Insulin regulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin regulation in men with NASH
Trial: 38901559
Drug: Insulin regulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin regulation in men with simple steatosis
Trial: 38901946
Drug: Daytime infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime infusions of HPN
Trial: 38901946
Drug: Overnight infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight infusions of HPN
Trial: 38902005
Drug: LEV 20
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 20 or 40 mg/kg bolus followed by 5 or 10 mg/kg maintenance dose daily (NEOLEV1)
Trial: 38902005
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg intravenous LEV load, followed by 10 mg/kg doses 8 hourly (NEOLEV2)
Trial: 38902005
Drug: Further 20
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further 20 mg/kg intravenous load if seizures persisted (NEOLEV2)
Trial: 38902571
Drug: ALZ-801 265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily)
Trial: 38902572
Drug: ALZ-801 265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ-801 265 mg two times daily (BID)
Trial: 38902616
Drug: Tablet-based educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based educational control
Trial: 38902691
Drug: Edaravone dexborneol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone dexborneol (37.5 mg/12 hours, IV)
Trial: 38902691
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no edaravone dexborneol treatment)
Trial: 38902747
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel administration
Trial: 38902846
Drug: InterCARE care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InterCARE care model integrating HIV and hypertension care through provider training, adapted electronic health record, and treatment partners (peer support)
Trial: 38902860
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of mRNA-1273 (100 μg)
Trial: 38902860
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of mRNA-1273 (2×100 μg)
Trial: 38902860
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Ad26.COV2.S (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein)
Trial: 38902860
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of mycophenolate mofetil/mycophenolic acid after vaccination
Trial: 38902928
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg yohimbine and 10 mg hydrocortisone
Trial: 38902952
Drug: Chemotherapy received
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy received locally